Most up-to-date research on "PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022" to its huge collection of research reports.

Albany, NY -- (SBWire) -- 06/25/2014 --PharmaPoint: Osteoporosis US Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Osteoporosis US Drug Forecast and Market Analysis to 2022. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the gold-standard bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lillys blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

Browse Detail Report With TOC @ http://www.researchmoz.us/pharmapoint-osteoporosis-us-drug-forecast-and-market-analysis-to-2022-report.html

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

The large dip in sales caused by these expiries is offset by six pipeline product launches over the forecast period, with three of these being potential blockbuster drugs. This next generation of drugs typically consists of biologics and will be higher priced than the drugs losing patent protection in the first half of the forecast period.

Scope

Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the US from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the US Osteoporosis market.

Browse Reports in Healthcare @ http://www.researchmoz.us/healthcare-market-reports-56.html

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in the US

About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:
Email: sales@researchmoz.us